Pulmonary tumor thrombotic microangiopathy (PTTM) causing fatal pulmonary hypertension is a rare presentation of malignancy. In general, patients with PTTM rapidly succumb to death due to severe hypoxia. To date, very few cases of PTTM have been reported in the literature; and most of these cases were from gastric cancer and were diagnosed on post mortem autopsy, as it is extremely challenging to make an ante mortem diagnosis. We here report on a case of undiagnosed diffuse gastric cancer, presenting as worsening hypoxia. The clinical, radiographic, and echocardiographic features, and laboratory and pathological results were consistent with PTTM from gastric cancer. The patient was started on anticoagulation therapy, corticosteroids, and high-flow oxygen. However, her hypoxia worsened to the extent that she required ventilator support, and she died soon after intubation due to cardiac arrest. Since diffuse gastric cancer is associated with hereditary diffuse gastric cancer syndrome, cadherin 1 gene mutation analysis was performed to estimate the risk to her daughters. The test came back negative.
Introduction
Pulmonary tumor thrombotic microangiopathy (PTTM), first defined by von Herbay et al. 1 in 1990, is a rare and fatal pulmonary complication associated with various malignancies. Based on limited retrospective case series and reports, it has been shown to be most frequently associated with gastric cancer. 1, 2 Most of the cases in the literature were diagnosed on postmortem autopsy, and ante mortem diagnosis is extremely challenging due to the rapid development of lethal pulmonary hypertension, heart failure, and death (Fig. 2) , and mucicarmine staining confirmed mucin secreting signet ring cells (Fig. 3) . A CT scan of the abdomen was performed to look for the primary tumor, and revealed a diffusely thickened stomach wall with enhancement consistent with diffuse gastric cancer (Fig.   4 ), in accordance with the signet ring adenocarcinomatous cells observed in the lymph node biopsy. At that time, the patient's plasma 
Discussion
Gastric cancer remains the second most common cause of cancer-related deaths worldwide. [3] [4] [5] Gastric carcinoma cells have a high tendency to metastasize to the lymph nodes and distant organs, 6 which is likely strongly associated with its poor prognosis. 7 In particular, carcinoma cells in the pulmonary artery significantly influence the risks of tumor recurrence and death after resection. 8 Moreover, these cells may also cause remodeling, especially asymmetric thickening of the intima of the pulmonary artery, which in turn may induce an increase in the pressure of the right ventricle.
One condition of remodeling is PTTM. PTTM, first described by von Herbay et al. 1 In a recent study of autopsy findings in gastric cancer by Ishiwatari et al., 16 cancer cells were present in the pulmonary arteries in 30.4% (51/168) of the cases, and this is known to increase the risk of cancer cell implantation in vessels and thereby the risk of developing of PTTM. In addition, diffuse-type gastric carcinoma may be apt to cause remodeling of the pulmonary artery.
It is extremely difficult to diagnose PTTM, and most of the patients rapidly succumb to death due to severe respiratory failure. In Diffuse gastric cancer, also known as signet ring carcinoma, is a poorly differentiated adenocarcinoma that infiltrates into the stomach wall, causing thickening of the wall (linitis plastica) without forming a distinct mass. HDGC is a subgroup of diffuse gastric cancer. 22 The average age of onset of HDGC is 38 years, and the CDH1 gene mutation is the only genetic mutation described so far that has been associated with the occurrence of HDGC (25%~50% of cases). 23 The recent consensus guidelines in 2010 have broadened the criteria of testing for the CDH1 gene mutation as follows: If positive, their offspring should subsequently be tested for the mutation as it has a high penetrance rate of 70% to 80%. In mutation-positive individuals, prophylactic total gastrectomy at a center of excellence should be strongly considered, as a systematic histological study of prophylactic gastrectomies almost universally showed pre-invasive lesions, including in situ signet ring carcinoma. 23 Our patient almost met the second criteria and since she had three children, we pursued genetic testing of the patient's serum.
Fortunately, the test was negative. Thus, it is important to consider the possibility of HDGC in similar patients.
In conclusion, PTTM is a lethal condition that tends to be frequently associated with gastric cancer especially poorly differentiated diffuse gastric cancer. It is important to increase the awareness of this condition and have high a clinical suspicion of this entity in appropriate setting as early diagnosis may improve the mortality from this fatal condition.
